Comparative Pharmacology
Head-to-head clinical analysis: INTRALIPID 20 versus LIQREV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTRALIPID 20 versus LIQREV.
INTRALIPID 20% vs LIQREV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intralipid 20% is a fat emulsion providing essential fatty acids and triglycerides. It serves as a source of calories and essential fatty acids. In parenteral nutrition, it prevents and treats essential fatty acid deficiency. In lipid rescue therapy for local anesthetic toxicity, it acts as a 'lipid sink' to sequester lipophilic drugs, and may also enhance mitochondrial fatty acid oxidation and improve cardiac contractility.
Liqrev (sildenafil) is a phosphodiesterase-5 (PDE5) inhibitor. It enhances the effect of nitric oxide by inhibiting PDE5, which degrades cGMP in the corpus cavernosum, leading to increased cGMP levels and smooth muscle relaxation, thereby facilitating penile erection.
Intravenous infusion at a rate of 0.1 g fat/kg/hour, increasing to 0.5 g fat/kg/hour if tolerated. Maximum daily dose: 2.5 g fat/kg (50 mL/kg/day of 20% emulsion).
LIQREV (ivermectin) 200 mcg/kg orally once, taken on an empty stomach with water.
None Documented
None Documented
Terminal elimination half-life of lipid particles: approximately 30 minutes for chylomicron-like particles; triglycerides half-life ~15-30 minutes. Clinical context: rapid clearance by lipoprotein lipase.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min).
Renal: negligible. Biliary/fecal: >90% as component of lipid metabolism, excretion via bile and fecal elimination of lipid particles.
Primarily renal (70% as unchanged drug, 15% as glucuronide conjugate); 10% biliary/fecal.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion